Last reviewed · How we verify
CLOBENZEPAM — Competitive Intelligence Brief
phase 2
clobenzepam
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
CLOBENZEPAM (CLOBENZEPAM). Clobenzepam is thought to work by interacting with the brain's GABA receptors to produce a calming effect.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CLOBENZEPAM TARGET | CLOBENZEPAM | phase 2 | clobenzepam |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (clobenzepam class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CLOBENZEPAM CI watch — RSS
- CLOBENZEPAM CI watch — Atom
- CLOBENZEPAM CI watch — JSON
- CLOBENZEPAM alone — RSS
- Whole clobenzepam class — RSS
Cite this brief
Drug Landscape (2026). CLOBENZEPAM — Competitive Intelligence Brief. https://druglandscape.com/ci/clobenzepam. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing